Diranersen Phase 2 & GLP-1 Frailty Signals: What Clinicians Must Know

247 Health News Editorial

·

16 July 2026

·

3 min read

·healthtech

Biogen's diranersen has shown Phase 2 cognitive benefit comparable to approved Alzheimer's therapies, with Phase 3 now planned. Separately, a large study flags frailty-related signals in older adults on tirzepatide — raising urgent questions about monitoring protocols as GLP-1 prescribing expands into aged care settings.

Originally reported by STAT News

References

  1. 1.Silverman, E. (2026, July 15). Pharmalittle: We're reading about a Biogen Alzheimer's drug, skyrocketing 340B drug sales, and more. STAT News. https://www.statnews.com/pharmalot/2026/07/15/biogen-alzheimer-drug-skyrocketing-340b-drug-sales/
  2. 2.Reuters Health Desk. (2026). Large study identifies frailty signals in older adults taking tirzepatide. Reuters. https://www.reuters.com
  3. 3.van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
  4. 4.Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., Solomon, P., Salloway, S., Apostolova, L. G., Hansson, O., Ritchie, C., Brooks, D. A., Mintun, M., & Siemers, E. (2023). Donanemab in early symptomatic Alzheimer's disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, 330(6), 512–527. https://doi.org/10.1001/jama.2023.13239
  5. 5.Clegg, A., Young, J., Iliffe, S., Rikkert, M. O., & Rockwood, K. (2013). Frailty in elderly people. The Lancet, 381(9868), 752–762. https://doi.org/10.1016/S0140-6736(12)62167-9
  6. 6.Batsis, J. A., & Villareal, D. T. (2018). Sarcopenic obesity in older adults: Aetiology, epidemiology and treatment strategies. Nature Reviews Endocrinology, 14(9), 513–537. https://doi.org/10.1038/s41574-018-0062-9
  7. 7.Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
  8. 8.Lim, W. S., Wong, S. F., Leong, I., Choo, P., & Pang, W. S. (2017). Forging a frailty-ready healthcare system to meet population ageing. International Journal of Environmental Research and Public Health, 14(12), 1448. https://doi.org/10.3390/ijerph14121448
Share:XLinkedIn
2

247 Health News Editorial

247 Health News is a medical intelligence platform delivering evidence-based research appraisals, clinical trial monitoring, and health technology news for healthcare professionals.

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service